JPWO2020128108A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020128108A5 JPWO2020128108A5 JP2021536201A JP2021536201A JPWO2020128108A5 JP WO2020128108 A5 JPWO2020128108 A5 JP WO2020128108A5 JP 2021536201 A JP2021536201 A JP 2021536201A JP 2021536201 A JP2021536201 A JP 2021536201A JP WO2020128108 A5 JPWO2020128108 A5 JP WO2020128108A5
- Authority
- JP
- Japan
- Prior art keywords
- rbp
- terminal
- seq
- domain
- lambda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710146873 Receptor-binding protein Proteins 0.000 claims 149
- 210000004899 c-terminal region Anatomy 0.000 claims 48
- 230000001580 bacterial effect Effects 0.000 claims 33
- 241001515965 unidentified phage Species 0.000 claims 28
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 102000039446 nucleic acids Human genes 0.000 claims 25
- 150000007523 nucleic acids Chemical class 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000003981 vehicle Substances 0.000 claims 24
- 230000003993 interaction Effects 0.000 claims 14
- 230000004927 fusion Effects 0.000 claims 12
- 241000894006 Bacteria Species 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000003780 insertion Methods 0.000 claims 6
- 230000037431 insertion Effects 0.000 claims 6
- 108010062877 Bacteriocins Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108020005004 Guide RNA Proteins 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 102000040739 Secretory proteins Human genes 0.000 claims 1
- 108091058545 Secretory proteins Proteins 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- 238000010459 TALEN Methods 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000003214 anti-biofilm Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 244000005702 human microbiome Species 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000000304 virulence factor Substances 0.000 claims 1
- 230000007923 virulence factor Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783258P | 2018-12-21 | 2018-12-21 | |
| US62/783,258 | 2018-12-21 | ||
| US201962802777P | 2019-02-08 | 2019-02-08 | |
| US62/802,777 | 2019-02-08 | ||
| US16/696,769 US11661443B2 (en) | 2018-11-27 | 2019-11-26 | Chimeric receptor binding proteins for use in bacterial delivery vehicles |
| EPPCT/EP2019/082640 | 2019-11-26 | ||
| US16/696,769 | 2019-11-26 | ||
| PCT/EP2019/082640 WO2020109339A1 (en) | 2018-11-27 | 2019-11-26 | Chimeric receptor binding proteins for use in bacterial delivery vehicles |
| PCT/EP2019/086990 WO2020128108A1 (en) | 2018-12-21 | 2019-12-23 | Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514700A JP2022514700A (ja) | 2022-02-14 |
| JPWO2020128108A5 true JPWO2020128108A5 (https=) | 2023-01-10 |
| JP2022514700A5 JP2022514700A5 (https=) | 2023-01-10 |
Family
ID=71101098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536201A Pending JP2022514700A (ja) | 2018-12-21 | 2019-12-23 | 細菌送達ビヒクルにおける使用のための分岐型受容体結合多サブユニットタンパク質複合体 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3898953A1 (https=) |
| JP (1) | JP2022514700A (https=) |
| KR (1) | KR20210107053A (https=) |
| CN (1) | CN113498435A (https=) |
| CA (1) | CA3120160A1 (https=) |
| IL (1) | IL283796A (https=) |
| WO (1) | WO2020128108A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584781B2 (en) | 2019-12-30 | 2023-02-21 | Eligo Bioscience | Chimeric receptor binding proteins resistant to proteolytic degradation |
| TR202014396A2 (tr) * | 2020-09-10 | 2022-03-21 | Univ Yildiz Teknik | Mikroorganizma hedefli, antimikrobiyal bileşen/bileşenler içeren nanoformülasyonlar. |
| WO2022144381A1 (en) * | 2020-12-30 | 2022-07-07 | Eligo Bioscience | Microbiome modulation of a host by delivery of dna payloads with minimized spread |
| JP2024520940A (ja) * | 2021-05-12 | 2024-05-27 | エリゴ・バイオサイエンス | 産生細菌細胞及び産生方法におけるその使用 |
| EP4342538A1 (en) * | 2022-09-20 | 2024-03-27 | Technische Universität München | Simultaneous production of structural proteins from heterologous bacteriophage in cell-free expression system |
| EP4615856A1 (en) * | 2022-11-10 | 2025-09-17 | Laboratory Corporation of America Holdings | Synthetic phage with recombinant tail-spike proteins and related methods |
| CN116003531B (zh) * | 2022-12-28 | 2023-09-05 | 山东省农业科学院畜牧兽医研究所 | 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10660943B2 (en) | 2013-02-07 | 2020-05-26 | The Rockefeller University | Sequence specific antimicrobials |
| EP3234136B1 (en) * | 2014-12-16 | 2024-08-21 | C3J Therapeutics, Inc. | Compositions of and methods for in vitro viral genome engineering |
-
2019
- 2019-12-23 KR KR1020217022651A patent/KR20210107053A/ko not_active Withdrawn
- 2019-12-23 EP EP19829637.8A patent/EP3898953A1/en not_active Withdrawn
- 2019-12-23 CA CA3120160A patent/CA3120160A1/en active Pending
- 2019-12-23 JP JP2021536201A patent/JP2022514700A/ja active Pending
- 2019-12-23 CN CN201980085305.8A patent/CN113498435A/zh active Pending
- 2019-12-23 WO PCT/EP2019/086990 patent/WO2020128108A1/en not_active Ceased
-
2021
- 2021-06-07 IL IL283796A patent/IL283796A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11485773B1 (en) | Protease inhibitor:protease sensitive expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria | |
| US20230212629A1 (en) | Compositions and methods for producing circular polyribonucleotides | |
| JP2021091689A (ja) | 核酸ワクチン | |
| TW202217003A (zh) | 經改造之肌肉靶向組合物 | |
| US20180049984A1 (en) | Carriers for Plasmid and RNP Delivery in the Treatment of Cancer and Other Disease States | |
| CN118846026A (zh) | 广谱流感病毒疫苗 | |
| JP2021513863A5 (https=) | ||
| KR102139844B1 (ko) | 암 표적화 치료용 알부민-결합 아르기닌 데이미나제를 포함하는 약제학적 조성물 | |
| JP2023524061A (ja) | 操作された中枢神経系用組成物 | |
| US20250002941A1 (en) | A bacteria-derived lipid composition and use thereof | |
| JP2002500662A (ja) | 核酸と細胞外マトリックスを崩壊させる物質とを組み合わせた遺伝子治療用組合せ製剤 | |
| US20190142744A1 (en) | Nucleic acid nanocages, compositions, and uses thereof | |
| CN104837506A (zh) | 免疫调节性小细胞及使用方法 | |
| EP4479542A1 (en) | Cell-type specific membrane fusion proteins | |
| He et al. | Advances in microbial decorations and its applications in drug delivery | |
| JPWO2020128108A5 (https=) | ||
| Sun et al. | The application of nucleic acids and nucleic acid materials in antimicrobial research | |
| TW202223095A (zh) | 串聯指環病毒構築體 | |
| JPWO2020109339A5 (https=) | ||
| ES2210308T3 (es) | Procedimiento de genoterapia que utiliza vectores de adn sin gen marcador de seleccion. | |
| US12037597B2 (en) | Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells | |
| US20250057956A1 (en) | Cell-type specific targeting contractile injection system | |
| Peng et al. | Harnessing mRNA for heart health: a new era in cardiovascular treatment | |
| Fialho et al. | Recent patents on bacterial proteins as potential anticancer agents | |
| JP2016526541A (ja) | アンチセンスオリゴヌクレオチド組成物 |